Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

Authors

  • Kathleen E. Corey M.D., M.P.H.,

    1. Division of Gastroenterology and Hepatology, Massachusetts General Hospital, Harvard Medical School, Cambridge, Massachusetts
    Search for more papers by this author
  • Naga Chalasani M.D., F.A.C.G.

    Corresponding author
    1. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana
    • Professor of Medicine and Cellular & Integrative Physiology, Director, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, RG 4100, 1050 Wishard Blvd., Indianapolis, IN 46202
    Search for more papers by this author
    • fax: 317-278-1949


  • Potential conflict of interest: Dr. Chalasani serves currently or served within last 12 months as a paid consultant to Amylin and Mochida in the areas related to NAFLD and NASH. He serves as a paid consultant to several other entities in the area of drug safety. This work is in part supported by K24 DK 069290A to N.C.

No abstract is available for this article.

Ancillary